Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28916103 | 0.81 | EPHX1 (0.52) | EPHX1 | |
| SCHEMBL28996704 | 0.81 | EPHX1 (0.46) | TDP1EPHX1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL29170600 | 0.79 | TDP1 (0.33) | NAAATDP1EPHX1ALDH1A1TSHR | |
| SCHEMBL30500332 | 0.78 | CHRNB2 (0.36) | NAAATDP1EPHX1ALDH1A1TSHR | |
| SCHEMBL28252136 | 0.77 | LMNA (0.33) | HSD17B10 | |
| SCHEMBL30816846 | 0.76 | TDP1 (0.31) | TDP1EPHX1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL14520407 | 0.76 | TDP1 (0.35) | TDP1EPHX1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL21912604 | 0.76 | TDP1 (0.36) | TDP1EPHX1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL27737956 | 0.76 | LMNA (0.32) | TDP1HSD17B10 | |
| SCHEMBL19307961 | 0.75 | EPHX1 (0.34) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | disclosed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | CACNA1E, CACNA1C, CACNA1S | NAAA 1959/4885TDP1 2887/4885EPHX1 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.